<DOC>
	<DOCNO>NCT01613755</DOCNO>
	<brief_summary>The antihyperglycemic drug metformin thrombocyte aggregation inhibitor dipyridamole often use concomitantly patient diabetes suffered transient ischemic attack stroke . It recently suggest gastrointestinal absorption metformin mediate equilibrative nucleoside transporter 4 ( hENT4 ) . Dipyridamole report inhibit hENT4 transport vitro . The aim research proposal study pharmacokinetic interaction metformin dipyridamole . The investigator hypothesize dipyridamole reduces gastrointestinal absorption metformin . If hypothesis confirm , result study explain part high variability plasma metformin concentration patient treat diabetes , use optimize pharmacotherapy patient diabetes .</brief_summary>
	<brief_title>Metformin-Dipyridamole Interaction Trial</brief_title>
	<detailed_description />
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Dipyridamole</mesh_term>
	<criteria>Age 1850 year Written inform consent Smoking Hypertension ( systolic blood pressure &gt; 140 mmHg and/or diastolic blood pressure &gt; 90 mmHg ) Diabetes Mellitus ( fast glucose &gt; 7.0 mmol/L random glucose &gt; 11 mmol/L ) History cardiovascular disease Concomitant use medication Renal dysfunction ( MDRD &lt; 60 ml/min ) ECG abnormality , fir grade AVblock right bundle branch block</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Effect Dipyridamole pharmacokinetics metformin</keyword>
</DOC>